Ra Pharmaceuticals Inc - Strategic SWOT Analysis Review

Ra Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The Publisher’s summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Ra Pharmaceuticals Inc (Ra Pharmaceuticals), a subsidiary of UCB SA is a clinical stage biopharmaceutical company that develops therapeutics for patients with rare diseases based on its Extreme Diversity technology platform. It has pipeline products in pre-clinical, Phase I and Phase II trials for CNS diseases, autoimmune and renal disorders. The company’s lead product candidate, Zilucoplan, is a self-administered subcutaneous (SC) injection for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). The company has collaboration with other companies to carry out the pre-clinical programs for glomerulonephritis (C3GN), and dense deposit disease (DDD). Ra Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Ra Pharmaceuticals Inc Key Recent Developments

Feb 28,2020: Ra Pharmaceuticals supports 13th Annual Rare Disease Day and joins global movement to raise awareness for rare diseases
Feb 27,2020: Ra Pharmaceuticals reports fourth quarter and full year 2019 financial results and provides corporate update

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the publisher’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.